Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 11;31(3):319-322.
doi: 10.1016/j.joco.2019.05.002. eCollection 2019 Sep.

Ocular adverse events with immune checkpoint inhibitors

Tony Fang  1 , David A Maberley  2 , Mahyar Etminan  2
Affiliations

Ocular adverse events with immune checkpoint inhibitors

Tony Fang et al. J Curr Ophthalmol. .

Abstract

Purpose: To quantify the risk of ocular adverse events with immune checkpoint inhibitors (ICIs) as reported to the Food and Drug Administration (FDA).

Methods: Disproportionality analysis using data from U.S. FDA's Adverse Events Reporting System (FAERS) database 2003 to 2018. Data from pharmaceutical manufacturers, healthcare providers, consumers in the U.S., and post-marketing clinical trial reports from U.S. and non-U.S. studies. All cases of uveitis, dry eye syndrome, ocular myasthenia and eye inflammation with use of the following ICIs: atezolizumab, avelumab, cemiplimab, durvalumab, ipilimumab, nivolumab and pembrolizumab. Reported odds ratios (RORs) and corresponding 95% confidence intervals (CIs) were computed for all drugs as a group or as individual agents.

Results: We identified 113 ocular adverse events for all ICIs of interest including uveitis, dry eye, ocular myasthenia and eye inflammation. Nivolumab had the highest number of adverse events (N = 68) associated with use of the ICI. Nivolumab had the highest association with ocular myasthenia [ROR = 22.82, 95% CI (7.18-72.50)] followed by pembrolizumab [ROR = 20.17, 95% CI (2.80-145.20)]. Among all ICIs approved in North America, atezolizumab had the highest association with eye inflammation [ROR = 18.89, 95% CI (6.07-58.81)] and ipilmumab had the highest association with uveitis [ROR = 10.54, 95% CI (7.30-15.22)].

Conclusion: The results of this disproportionality analysis suggest use of ICIs is associated with an increase risk for ocular adverse reactions. Future epidemiologic studies are needed to better quantify these adverse events.

Keywords: Disproportionality analysis; Drug-induced; Eye inflammation; Immune checkpoint inhibitors; Immunotherapy; Uveitis.

PubMed Disclaimer

References

    1. Hargadon K.M., Johnson C.E., Williams C.J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39. - PubMed
    1. Byun D., Wolchok J., Rosenberg L., Giotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):195–207. - PMC - PubMed
    1. Webb E.S., Liu P., Baleeiro R., Lemoine N.R., Yuan M., Wang Y. Immune checkpoint inhibitors in cancer therapy. J Biomed Res. 2017;32(5):317–326. - PMC - PubMed
    1. Johnson D., Chandra S., Sosman J. Immune checkpoint inhibitor toxicity in 2018. JAMA Insights. 2018;320(16):1702–1703. - PubMed
    1. El Osta B., Hu F., Sadek R., Chintalapally R., Tang S.C. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1–12. - PubMed

LinkOut - more resources